Payment overview · 2025
General Payments
$182.79
10 reported records · 7 companies
Healthcare provider profile · identity verified
Shafi Raza, MD
Allopathic & Osteopathic Physicians|Internal Medicine · OLEAN, NY · NPI 1811151160
Verified facts
What the public records show
CMS Open Payments records show Shafi Raza, MD received $182.79 in general payments during 2025 across 10 reported records.
Lilly USA, LLC accounted for 21.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 9 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Mounjaro, Rexulti, Trelegy Ellipta.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 187 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 71 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 115 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Rybelsus by this doctor in 2024.
Otsuka America Pharmaceutical, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported REXULTI as an associated drug or biological on 160756 records involving 46288 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Rexulti by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $38.93 | 21.3% | 2 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $36.59 | 20.0% | 2 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $32.30 | 17.7% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $24.75 | 13.5% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $18.16 | 9.9% | 1 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $16.84 | 9.2% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.22 | 8.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $182.79 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $38.93 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $38.93 | 2 | 2025 |
Source payment records
|
|||||
| Auvelity Normalized: auvelity |
Drug | Axsome Therapeutics, Inc. | $36.59 | 2 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $32.30 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $24.75 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $18.16 | 1 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $16.84 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.22 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 61 | exact normalized | Medicare Part D |
| REXULTI rexulti |
2025 | Rexulti | 2024 | 81 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 187 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
187 | 54 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
71 | 24 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
61 | 13 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
115 | 29 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Otsuka America Pharmaceutical, Inc. Exact reporting entity; no affiliate inference |
2025 | REXULTI open payments reported associated product |
CMS Open Payments — General Payments 160756 supporting records · 46288 recipient NPIs · example record 1227267708 |
Rexulti · 2024 Exact normalized brand match · 1 Part D row |
81 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 728 | 175 |
| Metoprolol Succinate | Metoprolol Succinate | 596 | 171 |
| Pantoprazole Sodium | Pantoprazole Sodium | 575 | 135 |
| Levothyroxine Sodium | Levothyroxine Sodium | 497 | 114 |
| Amlodipine Besylate | Amlodipine Besylate | 451 | 118 |
| Gabapentin | Gabapentin | 386 | 88 |
| Lisinopril | Lisinopril | 358 | 101 |
| Bumetanide | Bumetanide | 330 | 67 |
| Furosemide | Furosemide | 324 | 63 |
| Metformin Hcl | Metformin Hcl | 298 | 79 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 279 | 64 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 269 | 82 |
| Losartan Potassium | Losartan Potassium | 265 | 81 |
| Eliquis | Apixaban | 263 | 52 |
| Omeprazole | Omeprazole | 233 | 70 |
| Simvastatin | Simvastatin | 193 | 51 |
| Metoprolol Tartrate | Metoprolol Tartrate | 192 | 48 |
| Montelukast Sodium | Montelukast Sodium | 191 | 39 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 187 | 54 |
| Potassium Chloride | Potassium Chloride | 186 | 45 |
| Meloxicam | Meloxicam | 183 | 55 |
| Xarelto | Rivaroxaban | 173 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 163 | 69 |
| Clopidogrel | Clopidogrel Bisulfate | 162 | 43 |
| Prednisone | Prednisone | 159 | 118 |
| Pravastatin Sodium | Pravastatin Sodium | 155 | 18 |
| Sertraline Hcl | Sertraline Hcl | 155 | 35 |
| Tramadol Hcl | Tramadol Hcl | 153 | 51 |
| Mirtazapine | Mirtazapine | 151 | 28 |
| Tamsulosin Hcl | Tamsulosin Hcl | 148 | 38 |
| Trazodone Hcl | Trazodone Hcl | 145 | 27 |
| Famotidine | Famotidine | 142 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 138 | 41 |
| Donepezil Hcl | Donepezil Hcl | 137 | 12 |
| Quetiapine Fumarate | Quetiapine Fumarate | 135 | 23 |
| Alprazolam | Alprazolam | 130 | 46 |
| Carvedilol | Carvedilol | 123 | 33 |
| Escitalopram Oxalate | Escitalopram Oxalate | 118 | 29 |
| Celecoxib | Celecoxib | 115 | 28 |
| Oxycodone Hcl | Oxycodone Hcl | 115 | 26 |
| Ozempic | Semaglutide | 115 | 29 |
| Citalopram Hbr | Citalopram Hydrobromide | 113 | 23 |
| Duloxetine Hcl | Duloxetine Hcl | 113 | 32 |
| Azithromycin | Azithromycin | 109 | 92 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 93 | 81 |
| Baclofen | Baclofen | 92 | 16 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 89 | 24 |
| Allopurinol | Allopurinol | 86 | 30 |
| Atenolol | Atenolol | 84 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 84 | 37 |
| Warfarin Sodium | Warfarin Sodium | 84 | suppressed |
| Rexulti | Brexpiprazole | 81 | suppressed |
| Olanzapine | Olanzapine | 79 | suppressed |
| Spironolactone | Spironolactone | 74 | 22 |
| Alendronate Sodium | Alendronate Sodium | 73 | 18 |
| Pregabalin | Pregabalin | 73 | 16 |
| Jardiance | Empagliflozin | 71 | 24 |
| Januvia | Sitagliptin Phosphate | 70 | 12 |
| Ezetimibe | Ezetimibe | 69 | 18 |
| Lorazepam | Lorazepam | 67 | 30 |
| Valsartan | Valsartan | 67 | 13 |
| Amitriptyline Hcl | Amitriptyline Hcl | 66 | 17 |
| Memantine Hcl | Memantine Hcl | 63 | 13 |
| Metformin Hcl Er | Metformin Hcl | 62 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 61 | 16 |
| Mounjaro | Tirzepatide | 61 | 13 |
| Farxiga | Dapagliflozin Propanediol | 60 | 17 |
| Paroxetine Hcl | Paroxetine Hcl | 60 | 15 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 57 | 20 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 55 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 55 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 54 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 54 | suppressed |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 53 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 53 | 12 |
| Clonidine Hcl | Clonidine Hcl | 52 | suppressed |
| Finasteride | Finasteride | 52 | 15 |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 52 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 50 | 19 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 47 | 12 |
| Ondansetron Hcl | Ondansetron Hcl | 46 | 19 |
| Cefpodoxime Proxetil | Cefpodoxime Proxetil | 45 | 40 |
| Memantine Hcl Er | Memantine Hcl | 45 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 44 | 12 |
| Levofloxacin | Levofloxacin | 44 | 32 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 42 | 38 |
| Clonazepam | Clonazepam | 42 | suppressed |
| Gemtesa | Vibegron | 42 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 42 | 15 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 41 | 14 |
| Levetiracetam | Levetiracetam | 41 | 12 |
| Dicyclomine Hcl | Dicyclomine Hcl | 40 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 39 | suppressed |
| Glipizide | Glipizide | 39 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 39 | 16 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 38 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 36 | 33 |
| Lactulose | Lactulose | 36 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 36 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 35 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 35 | 13 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 35 | 13 |
| Amiodarone Hcl | Amiodarone Hcl | 34 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 34 | suppressed |
| Risperidone | Risperidone | 34 | suppressed |
| Bupropion Xl | Bupropion Hcl | 33 | suppressed |
| Glimepiride | Glimepiride | 33 | 11 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 32 | 29 |
| Entresto | Sacubitril/Valsartan | 32 | suppressed |
| Mometasone Furoate | Mometasone Furoate | 32 | 20 |
| Myrbetriq | Mirabegron | 31 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 30 | suppressed |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 29 | suppressed |
| Fenofibrate | Fenofibrate,micronized | 29 | suppressed |
| Ibuprofen | Ibuprofen | 28 | 12 |
| Lovastatin | Lovastatin | 28 | suppressed |
| Rybelsus | Semaglutide | 27 | suppressed |
| Synthroid | Levothyroxine Sodium | 27 | 11 |
| Trulicity | Dulaglutide | 27 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 26 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 26 | suppressed |
| Ondansetron Odt | Ondansetron | 26 | 11 |
| Hydralazine Hcl | Hydralazine Hcl | 25 | suppressed |
| Dapagliflozin | Dapagliflozin Propanediol | 24 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 24 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 23 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 23 | suppressed |
| Ramipril | Ramipril | 22 | suppressed |
| Fluconazole | Fluconazole | 21 | 14 |
| Methimazole | Methimazole | 20 | suppressed |
| Methylprednisolone | Methylprednisolone | 20 | 18 |
| Primidone | Primidone | 20 | suppressed |
| Torsemide | Torsemide | 20 | suppressed |
| Anastrozole | Anastrozole | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 19 | suppressed |
| Aripiprazole | Aripiprazole | 19 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 19 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 19 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 18 | suppressed |
| Ibu | Ibuprofen | 18 | suppressed |
| Lamotrigine | Lamotrigine | 18 | suppressed |
| Naproxen | Naproxen | 18 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Fentanyl | Fentanyl | 17 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 17 | 17 |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 17 | suppressed |
| Diazepam | Diazepam | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 16 | suppressed |
| Alfuzosin Hcl Er | Alfuzosin Hcl | 15 | suppressed |
| Brilinta | Ticagrelor | 15 | suppressed |
| Metolazone | Metolazone | 15 | suppressed |
| Nitroglycerin | Nitroglycerin | 15 | 14 |
| Nyamyc | Nystatin | 15 | suppressed |
| Clindamycin Hcl | Clindamycin Hcl | 14 | 12 |
| Irbesartan | Irbesartan | 14 | suppressed |
| Lamotrigine Er | Lamotrigine | 14 | suppressed |
| Nystatin | Nystatin | 14 | suppressed |
| Repatha Sureclick | Evolocumab | 14 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 13 | suppressed |
| Galantamine Er | Galantamine Hbr | 13 | suppressed |
| Latanoprost | Latanoprost | 13 | suppressed |
| Morphine Sulfate | Morphine Sulfate | 13 | 12 |
| Mupirocin | Mupirocin | 13 | 12 |
| Sumatriptan Succinate | Sumatriptan Succinate | 13 | suppressed |
| Tradjenta | Linagliptin | 13 | suppressed |
| Ketoconazole | Ketoconazole | 12 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 12 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 12 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 11 | suppressed |
| Cephalexin | Cephalexin | 11 | suppressed |
| Colchicine | Colchicine | 11 | suppressed |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 11 | suppressed |
| Paroxetine Er | Paroxetine Hcl | 11 | suppressed |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $182.79 · 10 records | Lilly USA, LLC | Auvelity, Cologuard Collection Kit, MOUNJARO, OTEZLA, REPATHA, REXULTI, TRELEGY ELLIPTA, Wegovy, ZEPBOUND | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Mounjaro play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with GlaxoSmithKline, LLC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error